We performed a prospective subgroup analysis of the Vax-On-Third-Profile study to investigate longitudinal changes in antibody titers following full-course of mRNA-BNT162b2 (tozinameran) immunization in patients with advanced breast cancer receiving CDK4/6 inhibitors or HER2-targeted agents. This evidence concerns the gene ERBB2 and breast carcinoma.